Table 1. Characteristics of patients overall, with and without breakthrough SARS-CoV-2 infection.
| Characteristic | Overall1, N = 133,191 | No Breakthrough Infection2, N = 125,2871 | Breakthrough Infection2, N = 7,9041 |
|---|---|---|---|
| Age | |||
| 18–39 | 19,936 (15%) | 18,189 (91%) | 1,747 (8.8%) |
| 40–59 | 41,874 (31%) | 39,071 (93%) | 2,803 (6.7%) |
| 60–79 | 58,857 (44%) | 56,105 (95%) | 2,752 (4.7%) |
| 80+ | 12,524 (9.4%) | 11,922 (95%) | 602 (4.8%) |
| Sex | |||
| Male | 49,846 (37%) | 46,992 (94%) | 2,854 (5.7%) |
| Female | 83,345 (63%) | 78,295 (94%) | 5,050 (6.1%) |
| Race | |||
| White | 112,542 (84%) | 106,077 (94%) | 6,465 (5.7%) |
| Asian | 6,453 (4.8%) | 5,930 (92%) | 523 (8.1%) |
| Black or African American | 8,206 (6.2%) | 7,729 (94%) | 477 (5.8%) |
| Other | 5,990 (4.5%) | 5,551 (93%) | 439 (7.3%) |
| Ethnicity | |||
| Not Hispanic, Latino, or Spanish | 126,136 (94.7%) | 118,887 (94%) | 7,249 (5.7%) |
| Hispanic, Latino, or Spanish | 7,055 (5.3%) | 6,400 (91%) | 655 (9.3%) |
| First Vaccine Type | |||
| Adenovirus vector | 4,194 (3.1%) | 3,984 (95%) | 210 (5.0%) |
| mRNA | 128,997 (97%) | 121,303 (94%) | 7,694 (6.0%) |
| Booster Type | |||
| Adenovirus vector | 835 (0.6%) | 782 (94%) | 53 (6.3%) |
| mRNA | 132, 279 (99%) | 124,434 (93.4%) | 7,845 (6.6%) |
| Other3 | 6 (<0.1%) | 6 (100%) | 0 (0%) |
| Unknown | 71 (<0.1%) | 65 (92%) | 6 (8.5%) |
| Vaccine Status | |||
| Boosted 2+ Times | 1,025 (0.8%) | 982 (96%) | 43 (4.2%) |
| Boosted Once | 132,166 (99%) | 124,305 (94%) | 7,861 (5.9%) |
| Days since booster | 58.00 (39.00, 75.00) | 58.00 (39.00, 75.00) | 59.00 (39.00, 79.00) |
| 15–29 | 20,431 (15%) | 19,210 (94%) | 1,221 (6.0%) |
| 30–59 | 50,458 (38%) | 47,625 (94%) | 2,833 (5.6%) |
| 60–89 | 43,353 (33%) | 40,596 (94%) | 2,757 (6.4%) |
| 90+ | 18,949 (14%) | 17,856 (94%) | 1,093 (5.8%) |
| Diabetes mellitus | 20,958 (16%) | 19,739 (94%) | 1,219 (5.8%) |
| Solid Organ Transplant | 860 (0.6%) | 779 (91%) | 81 (9.4%) |
| HIV/AIDS | 6,113 (4.6%) | 5,680 (93%) | 433 (7.1%) |
| Chronic Liver Disease | 4,665 (3.5%) | 4,343 (93%) | 322 (6.9%) |
| Chronic Renal Disease | 15,084 (11%) | 14,174 (94%) | 910 (6.0%) |
| End Stage Renal Disease | 940 (0.7%) | 835 (89%) | 105 (11%) |
| Stem Cell Transplant | 428 (0.3%) | 408 (95%) | 20 (4.7%) |
| Asthma | 16,546 (12%) | 15,308 (93%) | 1,238 (7.5%) |
| COPD | 5,098 (3.8%) | 4,753 (93%) | 345 (6.8%) |
| Cancer | 22,839 (17%) | 21,701 (95%) | 1,138 (5.0%) |
| Hypertension | 60,112 (45%) | 56,742 (94%) | 3,370 (5.6%) |
| Hematologic Malignancy | 2,936 (2.2%) | 2,762 (94%) | 174 (5.9%) |
| Immunodeficiencies | 11,865 (8.9%) | 11,113 (94%) | 752 (6.3%) |
| Obesity | 45,046 (34%) | 42,172 (94%) | 2,874 (6.4%) |
| Number of comorbidities | |||
| 0 | 30,359 (23%) | 28,524 (94%) | 1,835 (6.0%) |
| 1 | 32,422 (24%) | 30,495 (94%) | 1,927 (5.9%) |
| 2 | 27,528 (21%) | 25,971 (94%) | 1,557 (5.7%) |
| 3+ | 42,882 (32%) | 40,297 (94%) | 2,585 (6.0%) |
1n (col %); Median (IQR)
2n (row %); Median (IQR)
3Includes AstraZeneca, Novavax, and Sinopharm